Current concepts regarding the HTLV-1 receptor complex

Retrovirology

Volumn 7, Issue , 2010, Pages

  Ghez, David ^a,b   Lepelletier, Yves ^a   Jones, Kathryn S ^c   Pique, Claudine ^d,e   Hermine, Olivier ^a,f  

^a CNRS   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c SAIC FREDERICK INC   (United States)

^d INSTITUT COCHIN   (France)

^e INSERM   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; HUMAN T LYMPHOTROPIC VIRUS TYPE 1 RECEPTOR; NEUROPILIN 1; PROTEOHEPARAN SULFATE; SEMAPHORIN 3A; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VIRUS RECEPTOR;

BINDING SITE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEX FORMATION; DENDRITIC CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INNATE IMMUNITY; MEMBRANE FUSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; TARGET CELL; VIRION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; HUMAN; METABOLISM; PATHOGENICITY; PHYSIOLOGY; VIROLOGY;

HUMAN T-LYMPHOTROPIC VIRUS 1;

GLUCOSE TRANSPORTER TYPE 1; HEPARAN SULFATE PROTEOGLYCANS; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; NEUROPILIN-1; RECEPTORS, VIRUS; VIRUS ATTACHMENT;

EID: 78649366823     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-99     Document Type: Review

References (93)

1. Jin Q, Agrawal L, VanHorn-Ali Z, Alkhatib G. Infection of CD4+ T lymphocytes by the human T cell leukemia virus type 1 is mediated by the glucose transporter GLUT-1: evidence using antibodies specific to the receptor's large extracellular domain. Virology 2006, 349:184-196. 10.1016/j.virol.2006.01.045, 16519917.
2. Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003, 115:449-459. 10.1016/S0092-8674(03)00881-X, 14622599.
3. Jin Q, Alkhatib B, Cornetta K, Alkhatib G. Alternate receptor usage of neuropilin-1 and glucose transporter protein 1 by the human T cell leukemia virus type 1. Virology 2009, 396:203-212. 10.1016/j.virol.2009.10.015, 19913864.
4. Lambert S, Bouttier M, Vassy R, Seigneuret M, Petrow-Sadowski C, Janvier S, Heveker N, Ruscetti FW, Perret G, Jones KS, Pique C. HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165. Blood 2009, 113:5176-5185. 10.1182/blood-2008-04-150342, 2686187, 19270265.
5. Ghez D, Lepelletier Y, Lambert S, Fourneau JM, Blot V, Janvier S, Arnulf B, van Endert PM, Heveker N, Pique C, Hermine O. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J Virol 2006, 80:6844-6854. 10.1128/JVI.02719-05, 1489069, 16809290.
6. Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J Virol 2005, 79:12692-12702. 10.1128/JVI.79.20.12692-12702.2005, 1235841, 16188972.
7. Pinon JD, Klasse PJ, Jassal SR, Welson S, Weber J, Brighty DW, Sattentau QJ. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol 2003, 77:9922-9930. 10.1128/JVI.77.18.9922-9930.2003, 224595, 12941902.
8. Delamarre L, Rosenberg AR, Pique C, Pham D, Callebaut I, Dokhelar MC. The HTLV-I envelope glycoproteins: structure and functions. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13(Suppl 1):S85-91. 10.1097/00042560-199600001-00015, 8797709.
9. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888. 10.1126/science.280.5371.1884, 9632381.
10. Kobe B, Center RJ, Kemp BE, Poumbourios P. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc Natl Acad Sci USA 1999, 96:4319-4324. 10.1073/pnas.96.8.4319, 16330, 10200260.
11. Maerz AL, Center RJ, Kemp BE, Kobe B, Poumbourios P. Functional implications of the human T-lymphotropic virus type 1 transmembrane glycoprotein helical hairpin structure. J Virol 2000, 74:6614-6621. 10.1128/JVI.74.14.6614-6621.2000, 112171, 10864675.
12. Delamarre L, Pique C, Pham D, Tursz T, Dokhelar MC. Identification of functional regions in the human T-cell leukemia virus type I SU glycoprotein. J Virol 1994, 68:3544-3549. 236858, 8189493.
13. Pique C, Tursz T, Dokhelar MC. Mutations introduced along the HTLV-I envelope gene result in a non-functional protein: a basis for envelope conservation?. Embo J 1990, 9:4243-4248. 552206, 2124968.
14. Jassal SR, Lairmore MD, Leigh-Brown AJ, Brighty DW. Soluble recombinant HTLV-1 surface glycoprotein competitively inhibits syncytia formation and viral infection of cells. Virus Res 2001, 78:17-34. 10.1016/S0168-1702(01)00279-9, 11520577.
15. Li K, Zhang S, Kronqvist M, Wallin M, Ekstrom M, Derse D, Garoff H. Intersubunit disulfide isomerization controls membrane fusion of human T-cell leukemia virus Env. J Virol 2008, 82:7135-7143. 10.1128/JVI.00448-08, 2446982, 18480461.
16. Sommerfelt MA. Retrovirus receptors. J Gen Virol 1999, 80(Pt 12):3049-3064.
17. Fan N, Gavalchin J, Paul B, Wells KH, Lane MJ, Poiesz BJ. Infection of peripheral blood mononuclear cells and cell lines by cell-free human T-cell lymphoma/leukemia virus type I. J Clin Microbiol 1992, 30:905-910. 265183, 1572977.
18. Derse D, Hill SA, Lloyd PA, Chung H, Morse BA. Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. J Virol 2001, 75:8461-8468. 10.1128/JVI.75.18.8461-8468.2001, 115091, 11507191.
19. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol 1990, 64:5682-5687. 248630, 1976827.
20. Hanon E, Stinchcombe JC, Saito M, Asquith BE, Taylor GP, Tanaka Y, Weber JN, Griffiths GM, Bangham CR. Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity 2000, 13:657-664. 10.1016/S1074-7613(00)00065-0, 11114378.
21. Koyanagi Y, Itoyama Y, Nakamura N, Takamatsu K, Kira J, Iwamasa T, Goto I, Yamamoto N. In vivo infection of human T-cell leukemia virus type I in non-T cells. Virology 1993, 196:25-33. 10.1006/viro.1993.1451, 8356797.
22. Nath MD, Ruscetti FW, Petrow-Sadowski C, Jones KS. Regulation of the cell-surface expression of an HTLV-I binding protein in human T cells during immune activation. Blood 2003, 101:3085-3092. 10.1182/blood-2002-07-2277, 12506039.
23. Knight SC, Macatonia SE, Cruickshank K, Rudge P, Patterson S. Dendritic cells in HIV-1 and HTLV-1 infection. Adv Exp Med Biol 1993, 329:545-549.
24. Macatonia SE, Cruickshank JK, Rudge P, Knight SC. Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation. AIDS Res Hum Retroviruses 1992, 8:1699-1706. 10.1089/aid.1992.8.1699, 1457215.
25. Setoyama M, Kerdel FA, Elgart G, Kanzaki T, Byrnes JJ. Detection of HTLV-1 by polymerase chain reaction in situ hybridization in adult T-cell leukemia/lymphoma. Am J Pathol 1998, 152:683-689. 1858394, 9502410.
26. Suzuki M, Matsuoka H, Yamashita K, Maeda K, Kawano K, Uno H, Tsubouchi H. CD45RO expression on peripheral lymphocytes as a prognostic marker for adult T-cell leukemia. Leuk Lymphoma 1998, 28:583-590.
27. Ruben S, Poteat H, Tan TH, Kawakami K, Roeder R, Haseltine W, Rosen CA. Cellular transcription factors and regulation of IL-2 receptor gene expression by HTLV-I tax gene product. Science 1988, 241:89-92. 10.1126/science.2838905, 2838905.
28. Yamano Y, Takenouchi N, Li HC, Tomaru U, Yao K, Grant CW, Maric DA, Jacobson S. Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest 2005, 115:1361-1368. 1087174, 15864353.
29. Lohr J, Knoechel B, Abbas AK. Regulatory T cells in the periphery. Immunol Rev 2006, 212:149-162. 10.1111/j.0105-2896.2006.00414.x, 16903912.
30. Toulza F, Nosaka K, Takiguchi M, Pagliuca T, Mitsuya H, Tanaka Y, Taylor GP, Bangham CR. FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. Int J Cancer 2009, 125:2375-2382. 10.1002/ijc.24664, 19544530.
31. Abe M, Uchihashi K, Kazuto T, Osaka A, Yanagihara K, Tsukasaki K, Hasegawa H, Yamada Y, Kamihira S. Foxp3 expression on normal and leukemic CD4+CD25+ T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells. Eur J Haematol 2008, 81:209-217. 10.1111/j.1600-0609.2008.01105.x, 18510697.
32. Yano H, Ishida T, Inagaki A, Ishii T, Kusumoto S, Komatsu H, Iida S, Utsunomiya A, Ueda R. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 2007, 120:2052-2057. 10.1002/ijc.22536, 17278106.
33. Chen S, Ishii N, Ine S, Ikeda S, Fujimura T, Ndhlovu LC, Soroosh P, Tada K, Harigae H, Kameoka J, Kasai N, Sasaki T, Sugamura K. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int Immunol 2006, 18:269-277. 10.1093/intimm/dxh366, 16361311.
34. Grant C, Oh U, Yao K, Yamano Y, Jacobson S. Dysregulation of TGF-beta signaling and regulatory and effector T-cell function in virus-induced neuroinflammatory disease. Blood 2008, 111:5601-5609. 10.1182/blood-2007-11-123430, 2424157, 18326816.
35. Toulza F, Heaps A, Tanaka Y, Taylor GP, Bangham CR. High frequency of CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood 2008, 111:5047-5053. 10.1182/blood-2007-10-118539, 2602587, 18094326.
36. Trejo SR, Ratner L. The HTLV receptor is a widely expressed protein. Virology 2000, 268:41-48. 10.1006/viro.2000.0143, 10683325.
37. Okuma K, Nakamura M, Nakano S, Niho Y, Matsuura Y. Host range of human T-cell leukemia virus type I analyzed by a cell fusion-dependent reporter gene activation assay. Virology 1999, 254:235-244. 10.1006/viro.1998.9530, 9986790.
38. Sutton RE, Littman DR. Broad host range of human T-cell leukemia virus type 1 demonstrated with an improved pseudotyping system. J Virol 1996, 70:7322-7326. 190797, 8794391.
39. Jassal SR, Pohler RG, Brighty DW. Human T-cell leukemia virus type 1 receptor expression among syncytium-resistant cell lines revealed by a novel surface glycoprotein-immunoadhesin. J Virol 2001, 75:8317-8328. 10.1128/JVI.75.17.8317-8328.2001, 115076, 11483777.
40. Manel N, Kinet S, Battini JL, Kim FJ, Taylor N, Sitbon M. The HTLV receptor is an early T-cell activation marker whose expression requires de novo protein synthesis. Blood 2003, 101:1913-1918. 10.1182/blood-2002-09-2681, 12393496.
41. Jones KS, Akel S, Petrow-Sadowski C, Huang Y, Bertolette DC, Ruscetti FW. Induction of human T cell leukemia virus type I receptors on quiescent naive T lymphocytes by TGF-beta. J Immunol 2005, 174:4262-4270.
42. Moriuchi M, Moriuchi H. Transforming growth factor-beta enhances human T-cell leukemia virus type I infection. J Med Virol 2002, 67:427-430. 10.1002/jmv.10074, 12116037.
43. Sommerfelt MA, Williams BP, Clapham PR, Solomon E, Goodfellow PN, Weiss RA. Human T cell leukemia viruses use a receptor determined by human chromosome 17. Science 1988, 242:1557-1559. 10.1126/science.3201246, 3201246.
44. Agadjanyan MG, Chattergoon MA, Petrushina I, Bennett M, Kim J, Ugen KE, Kieber-Emmons T, Weiner DB. Monoclonal antibodies define a cellular antigen involved in HTLV-I infection. Hybridoma 1998, 17:9-19. 10.1089/hyb.1998.17.9, 9523233.
45. Imai T, Fukudome K, Takagi S, Nagira M, Furuse M, Fukuhara N, Nishimura M, Hinuma Y, Yoshie O. C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. J Immunol 1992, 149:2879-2886.
46. Imai T, Yoshie O. C33 antigen and M38 antigen recognized by monoclonal antibodies inhibitory to syncytium formation by human T cell leukemia virus type 1 are both members of the transmembrane 4 superfamily and associate with each other and with CD4 or CD8 in T cells. J Immunol 1993, 151:6470-6481.
47. Hildreth JE. Syncytium-inhibiting monoclonal antibodies produced against human T-cell lymphotropic virus type 1-infected cells recognize class II major histocompatibility complex molecules and block by protein crowding. J Virol 1998, 72:9544-9552. 110458, 9811687.
48. Daenke S, McCracken SA, Booth S. Human T-cell leukaemia/lymphoma virus type 1 syncytium formation is regulated in a cell-specific manner by ICAM-1, ICAM-3 and VCAM-1 and can be inhibited by antibodies to integrin beta2 or beta7. J Gen Virol 1999, 80(Pt 6):1429-1436.
49. Sagara Y, Ishida C, Inoue Y, Shiraki H, Maeda Y. 71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human T-cell lymphotropic virus type 1. J Virol 1998, 72:535-541. 109405, 9420256.
50. Fang D, Haraguchi Y, Jinno A, Soda Y, Shimizu N, Hoshino H. Heat shock cognate protein 70 is a cell fusion-enhancing factor but not an entry factor for human T-cell lymphotropic virus type I. Biochem Biophys Res Commun 1999, 261:357-363. 10.1006/bbrc.1999.1028, 10425190.
51. Pique C, Lagaudriere-Gesbert C, Delamarre L, Rosenberg AR, Conjeaud H, Dokhelar MC. Interaction of CD82 tetraspanin proteins with HTLV-1 envelope glycoproteins inhibits cell-to-cell fusion and virus transmission. Virology 2000, 276:455-465. 10.1006/viro.2000.0538, 11040136.
52. Kim FJ, Manel N, Garrido EN, Valle C, Sitbon M, Battini JL. HTLV-1 and -2 envelope SU subdomains and critical determinants in receptor binding. Retrovirology 2004, 1:41. 10.1186/1742-4690-1-41, 539286, 15575958.
53. Kim FJ, Seiliez I, Denesvre C, Lavillette D, Cosset FL, Sitbon M. Definition of an amino-terminal domain of the human T-cell leukemia virus type 1 envelope surface unit that extends the fusogenic range of an ecotropic murine leukemia virus. J Biol Chem 2000, 275:23417-23420. 10.1074/jbc.C901002199, 10851227.
54. Manel N, Battini JL, Sitbon M. Human T cell leukemia virus envelope binding and virus entry are mediated by distinct domains of the glucose transporter GLUT1. J Biol Chem 2005, 280:29025-29029. 10.1074/jbc.M504549200, 15955807.
55. Coskun AK, Sutton RE. Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion. J Virol 2005, 79:4150-4158. 10.1128/JVI.79.7.4150-4158.2005, 1061550, 15767416.
56. Jin Q, Agrawal L, Vanhorn-Ali Z, Alkhatib G. GLUT-1-independent infection of the glioblastoma/astroglioma U87 cells by the human T cell leukemia virus type 1. Virology 2006, 353:99-110. 10.1016/j.virol.2006.05.003, 16781755.
57. Takenouchi N, Jones KS, Lisinski I, Fugo K, Yao K, Cushman SW, Ruscetti FW, Jacobson S. GLUT1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1. J Virol 2007, 81:1506-1510. 10.1128/JVI.01522-06, 1797527, 17108050.
58. Jones KS, Huang YK, Chevalier SA, Afonso PV, Petrow-Sadowski C, Bertolette DC, Gessain A, Ruscetti FW, Mahieux R. The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2. J Virol 2009, 83:5244-5255. 10.1128/JVI.02285-08, 2682092, 19279090.
59. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037. 10.1038/nature05817, 17460664.
60. Vives RR, Lortat-Jacob H, Fender P. Heparan sulphate proteoglycans and viral vectors: ally or foe?. Curr Gene Ther 2006, 6:35-44. 10.2174/156652306775515565, 16475944.
61. Mondor I, Ugolini S, Sattentau QJ. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 1998, 72:3623-3634. 109583, 9557643.
62. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 1999, 99:13-22. 10.1016/S0092-8674(00)80058-6, 10520990.
63. Ibrahim J, Griffin P, Coombe DR, Rider CC, James W. Cell-surface heparan sulfate facilitates human immunodeficiency virus Type 1 entry into some cell lines but not primary lymphocytes. Virus Res 1999, 60:159-169. 10.1016/S0168-1702(99)00018-0, 10392724.
64. Pais-Correia AM, Sachse M, Guadagnini S, Robbiati V, Lasserre R, Gessain A, Gout O, Alcover A, Thoulouze MI. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med 2009, 16:83-89. 10.1038/nm.2065, 20023636.
65. Gauthier S, Pelletier I, Ouellet M, Vargas A, Tremblay MJ, Sato S, Barbeau B. Induction of galectin-1 expression by HTLV-I Tax and its impact on HTLV-I infectivity. Retrovirology 2008, 5:105. 10.1186/1742-4690-5-105, 2613925, 19032754.
66. Jones KS, Fugo K, Petrow-Sadowski C, Huang Y, Bertolette DC, Lisinski I, Cushman SW, Jacobson S, Ruscetti FW. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells. J Virol 2006, 80:8291-8302. 10.1128/JVI.00389-06, 1563841, 16912281.
67. Sommerfelt MA, Weiss RA. Receptor interference groups of 20 retroviruses plating on human cells. Virology 1990, 176:58-69. 10.1016/0042-6822(90)90230-O, 1691887.
68. Xie L, Green PL. Envelope is a major viral determinant of the distinct in vitro cellular transformation tropism of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2. J Virol 2005, 79:14536-14545. 10.1128/JVI.79.23.14536-14545.2005, 1287554, 16282453.
69. Reeves JD, Hibbitts S, Simmons G, McKnight A, Azevedo-Pereira JM, Moniz-Pereira J, Clapham PR. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 1999, 73:7795-7804. 104307, 10438870.
70. Tordjman R, Lepelletier Y, Lemarchandel V, Cambot M, Gaulard P, Hermine O, Romeo PH. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002, 3:477-482.
71. Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther 2006, 5:1099-1107. 10.1158/1535-7163.MCT-05-0538, 16731741.
72. Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med 2008, 14:429-436. 10.1038/nm1745, 18376405.
73. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745. 10.1016/S0092-8674(00)81402-6, 9529250.
74. Lepelletier Y, Moura IC, Hadj-Slimane R, Renand A, Fiorentino S, Baude C, Shirvan A, Barzilai A, Hermine O. Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization. Eur J Immunol 2006, 36:1782-1793. 10.1002/eji.200535601, 16791896.
75. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, Tanaka Y, Osame M, Bangham CR. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003, 299:1713-1716. 10.1126/science.1080115, 12589003.
76. Crublet E, Andrieu JP, Vives RR, Lortat-Jacob H. The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site. J Biol Chem 2008, 283:15193-15200. 10.1074/jbc.M800066200, 18378683.
77. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci USA 2007, 104:6152-6157. 10.1073/pnas.0700043104, 1851056, 17405859.
78. Palker TJ, Riggs ER, Spragion DE, Muir AJ, Scearce RM, Randall RR, McAdams MW, McKnight A, Clapham PR, Weiss RA, et al. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins. J Virol 1992, 66:5879-5889. 241464, 1326649.
79. Chanel C, Staropoli I, Baleux F, Amara A, Valenzuela-Fernandez A, Virelizier JL, Arenzana-Seisdedos F, Altmeyer R. Low levels of co-receptor CCR5 are sufficient to permit HIV envelope-mediated fusion with resting CD4 T cells. Aids 2002, 16:2337-2340. 10.1097/00002030-200211220-00016, 12441808.
80. Bunn RC, Jensen MA, Reed BC. Protein interactions with the glucose transporter binding protein GLUT1CBP that provide a link between GLUT1 and the cytoskeleton. Mol Biol Cell 1999, 10:819-832. 25204, 10198040.
81. Cai H, Reed RR. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J Neurosci 1999, 19:6519-6527.
82. Grootjans JJ, Zimmermann P, Reekmans G, Smets A, Degeest G, Durr J, David G. Syntenin, a PDZ protein that binds syndecan cytoplasmic domains. Proc Natl Acad Sci USA 1997, 94:13683-13688. 10.1073/pnas.94.25.13683, 28366, 9391086.
83. Yoshida S, Higuchi M, Shoji T, Yoshita M, Ishioka K, Takahashi M, Oie M, Tanaka Y, Uchiyama M, Fujii M. Knockdown of synapse-associated protein Dlg1 reduces syncytium formation induced by human T-cell leukemia virus type 1. Virus Genes 2008, 37:9-15. 10.1007/s11262-008-0234-0, 18461433.
84. Azakami K, Sato T, Araya N, Utsunomiya A, Kubota R, Suzuki K, Hasegawa D, Izumi T, Fujita H, Aratani S, Fujii R, Yagishita N, Kamijuku H, Kanekura T, Seino K, Nishioka K, Nakajima T, Yamano Y. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood 2009 114:3208-15.
85. Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N, Uchiyama T. Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br J Haematol 2004, 125:568-575. 10.1111/j.1365-2141.2004.04956.x, 15147371.
86. Colisson R, Barblu L, Gras C, Raynaud F, Hadj-Slimane R, Pique C, Hermine O, Lepelletier Y, Herbeuval JP. Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. Blood 2009, 115:2177-2185. 10.1182/blood-2009-06-224741, 20007807.
87. El-Sabban ME, Merhi RA, Haidar HA, Arnulf B, Khoury H, Basbous J, Nijmeh J, de The H, Hermine O, Bazarbachi A. Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood 2002, 99:3383-3389. 10.1182/blood.V99.9.3383, 11964307.
88. Oh H, Takagi H, Otani A, Koyama S, Kemmochi S, Uemura A, Honda Y. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA 2002, 99:383-388. 10.1073/pnas.012074399, 117569, 11756651.
89. Sherer NM, Lehmann MJ, Jimenez-Soto LF, Horensavitz C, Pypaert M, Mothes W. Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat Cell Biol 2007, 9:310-315. 10.1038/ncb1544, 2628976, 17293854.
90. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002, 16:2684-2698. 10.1101/gad.242002, 187458, 12381667.
91. Bazarbachi A, Abou Merhi R, Gessain A, Talhouk R, El-Khoury H, Nasr R, Gout O, Sulahian R, Homaidan F, de T, Hermine O, El-Sabban ME. Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. Cancer Res 2004, 15:2039-46.
92. El-Sabban ME, Merhi RA, Haidar HA, Arnulf B, Khoury H, Basbous J, Nijmeh J, de Thé H, Hermine O, Bazarbachi A. Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood 2002, 99:3383-9. 10.1182/blood.V99.9.3383, 11964307.
93. Nakamura F, Tanaka M, Takahashi T, Kalb RG, Strittmatter SM. Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse. Neuron 1998, 21:1093-1100. 10.1016/S0896-6273(00)80626-1, 9856464.